Other trials with buparlisib in breast cancer are employing similar approaches, including a placebo-controlled phase II trial with paclitaxel in the first-line treatment of HER2-negative metastatic breast cancer (BELLE-4; NCT01572727), and a phase II trial of neoadjuvant paclitaxel plus trastuzumab, with and without buparlisib (Neo-PHOEBE) in HER2-overexpressing breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.